Transcriptional Regulation of GATA-1

Lead Research Organisation: University of Oxford

Abstract

A common cause of severe anaemia that can progress to leukaemia is known as myelodysplasia. In this condition blood cell precursors are made but fail to mature properly and do not function appropriately. Understanding this disorder depends on knowing how blood cells are normally made and mature in the bone marrow.||Our interest has focused on one critical factor that is required in this process, which is called GATA-1. GATA-1 co-ordinates many aspects of the normal maturation programme of blood and we wish to aspects of it biology.

Technical Summary

A key biological question, relevant to all differentiating tissues, is how multiple cell types arise from a pluripotential cell. When this process is perturbed it leads to human disease. We are using the haemopoietic system to study this question as it provides a good scientific and clinical model. Our laboratory is focused on how the erythroid and megakaryocytic lineages are specified and mature from a progenitor cell. Our particular interest is the role key transcription factors play in these processes. In particular, the zinc-finger transcription factor GATA-1 is absolutely required for the proper maturation of both the red cell and megakaryocyte lineages. In addition, GATA-1 expression is initiated in early haematopoietic progenitor at low level but then is restricted to principally erythroid and megakaryocytic cells where it is expressed at high level.||Our aim is to understand the molecular mechanisms that result in the tissue- and developmental- specific pattern of expression. As a consequence of these studies we hope to identify the transcriptional regulators that lie upstream of GATA-1 and thus help to specify the erythroid and megakaryocyte lineages.||Our approach to this problem is to try and identify all the cis-acting elements that are required for GATA-1 expression and the trans-acting factors that bind to them. We are identifying putative cis-elements in the GATA-1 locus by DNase I hypersensitivity analysis and by pin-pointing non-coding sequence that is conserved in evolution between mouse and human. Once putative cis-elements have been identified we are testing if they have function in stable cell transfection assays and in transgenic mice. Protein-DNA interactions at functionally important elements will be then be determined. Lastly, the functional importance of selected elements will be further examined by deleting them by homologous recombination in mice.

Publications

10 25 50

publication icon
Craddock C (2021) Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology

publication icon
DiNardo CD (2021) Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology

 
Description NHSBT Non Executive Director
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Ensuring quality and safe provision of blood and organs - Stem cells for England.
 
Description NHSBT Non-Executive Director
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Ensuring quality and safe provision of blood and organs.
 
Description NHSBT Non-Executive Director
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Ensuring quality and safe provision of blood and organs - Stem cells for England.
 
Description 0011150 CF
Amount £241,600 (GBP)
Organisation University of Oxford 
Department John Fell Fund
Sector Academic/University
Country United Kingdom
Start 11/2021 
End 09/2022
 
Description 2009 Disease Team Award
Amount £2,200,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2010 
End 05/2014
 
Description Amendment 4 Collaboration CyTOF Panels Mount Sinai
Amount £43,800 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 09/2019 
End 09/2022
 
Description BD - Celgene Fellowship Agreement for Supat Thongjuea entitled "Single-Cell Computational Biology for Translational Medicine
Amount £519,623 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 11/2019 
End 10/2022
 
Description BRC3 - Precision Medicine cluster funding
Amount £112,500 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2019 
End 03/2020
 
Description Blood Cancer UK - Programme Continuity Grant
Amount £300,000 (GBP)
Organisation Blood Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 04/2024
 
Description Celgene PhD Studentship
Amount £174,000 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 08/2010 
End 08/2013
 
Description Celgene Translational Science Proposal
Amount £1,065,908 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 09/2019 
End 01/2023
 
Description HIDI Award
Amount £25,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 07/2018 
End 07/2019
 
Description Leukaemia Research Specialist Programme Grant 2008
Amount £1,034,000 (GBP)
Organisation Leukaemia and Lymphoma Research 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2008 
End 07/2013
 
Description MRC Molecular Haematology Unit Award
Amount £520,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2013 
End 03/2017
 
Description Medical Research Council (MRC) - Molecular Haematology Unit Award
Amount £1,387,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 04/2022
 
Description Oxford Comprehensive Biomedical Research Centre
Amount £60,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2018 
End 04/2022
 
Description WIMM - Lymphoma Biobank
Amount £44,500 (GBP)
Organisation Oxford University Hospitals NHS Foundation Trust 
Sector Academic/University
Country United Kingdom
Start 11/2021 
End 10/2022
 
Description WIMM - TAL Wolfson Donation
Amount £750,000 (GBP)
Organisation The Wolfson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2021 
End 05/2023
 
Description WIMM LadyTata- A Groom
Amount £75,000 (GBP)
Organisation Lady Tata Memorial Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2021 
End 09/2023
 
Description WIMM-Celgene F'ship 21-2
Amount £543,000 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 03/2021 
End 10/2022
 
Description Development of novel therapeutic anti-leuakemia stem cell antibodies 
Organisation Barts Health NHS Trust
Department Department of Haematology
Country United Kingdom 
Sector Hospitals 
PI Contribution We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.
Collaborator Contribution It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data
Impact Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143
Start Year 2007
 
Description Development of novel therapeutic anti-leuakemia stem cell antibodies 
Organisation Cardiff University
Department Haematology
Country United Kingdom 
Sector Academic/University 
PI Contribution We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.
Collaborator Contribution It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data
Impact Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143
Start Year 2007
 
Description Development of novel therapeutic anti-leuakemia stem cell antibodies 
Organisation Queen Elizabeth Hospital Birmingham
Country United Kingdom 
Sector Hospitals 
PI Contribution We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.
Collaborator Contribution It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data
Impact Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143
Start Year 2007
 
Description Development of novel therapeutic anti-leuakemia stem cell antibodies 
Organisation Stanford University
Country United States 
Sector Academic/University 
PI Contribution We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.
Collaborator Contribution It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data
Impact Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143
Start Year 2007
 
Description Downs Syndrome associated preleukaemia and leukaemia 
Organisation Imperial College London
Department Centre for Haematology
Country United Kingdom 
Sector Academic/University 
PI Contribution We provide the majority of the research effort in this collaborative programme. We study the molecular and cellular basis of leukaemia using patient samples and mouse models that we are generating.
Collaborator Contribution We have a joint programme of work including a joint LLR Programme grant
Impact Grants 2008 Leukaemia Research 5-year Programme Grant, £1.03 M Publications (PubMed ID below): 19594743 18242315 18689547 18059480 18625887 17804520 17644747 17224656 17064858
Start Year 2006
 
Description Advising LLR to identify and prioritise the needs of blood cancer patients 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact 1. Helped fund raising.
2. Helped public awareness
3. Helped improve public advocacy

1. £15 000 were raised.
2. I have been asked to write booklet for patients with Acute Myeloid Leukaemia.
3. I have been asked to give a talk to members of Parliament.
Year(s) Of Engagement Activity 2014
 
Description Hosted Work Experience Programme 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Run a session on haematology for students in the MRC WIMM work experience programme. Included go fish game, activities on gene expression using legos and microscopy and leukaemia diagnosis
Year(s) Of Engagement Activity 2019
 
Description MRC Festival 2019 on Cancer immunotherapy - Grigore 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Part of working group that developed activities for MRC Festival 2019 on Cancer immunotherapy
Year(s) Of Engagement Activity 2019
 
Description OXFORD & NATIONWIDE SUPPORT GROUP MEETING - MDS UK Members 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Speaker at OXFORD & NATIONWIDE SUPPORT GROUP MEETING - MDS UK Members
Year(s) Of Engagement Activity 2021
 
Description Patient Support Group 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Giving support and advice to patients, families and carers.
Year(s) Of Engagement Activity 2019
 
Description Science Week 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Oxford Science Week is held annually to an audience of scientists and the general public.

Good feedback from schools
Year(s) Of Engagement Activity 2006,2007,2008,2009,2014
 
Description Science in the supermarket, MRC Festival 2019 - Douzi & Grigore 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Science in the supermarket, MRC Festival 2019
Year(s) Of Engagement Activity 2019
 
Description Student Presentations 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Final year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually.

Improved student training.
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010